Welcome to our dedicated page for Minerva Neurosci news (Ticker: NERV), a resource for investors and traders seeking the latest updates and insights on Minerva Neurosci stock.
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company developing product candidates for central nervous system (CNS) disorders, with a lead focus on roluperidone for negative symptoms of schizophrenia. The NERV news feed on Stock Titan aggregates company-issued updates and market-moving disclosures so readers can follow how Minerva’s clinical, regulatory and financing milestones evolve over time.
Recent news from Minerva highlights its ongoing interactions with the U.S. Food and Drug Administration (FDA) following a Complete Response Letter to its New Drug Application for roluperidone, as well as the agency’s requirement for a confirmatory Phase 3 trial. The company has released details about the planned trial design, including patient selection criteria, dosing, and the primary efficacy endpoint based on the PANSS Marder negative symptoms factor score.
Investors tracking NERV can also find announcements about Minerva’s private placement financing involving Series A Convertible Preferred Stock and warrants, which the company expects to use to fund the confirmatory Phase 3 study, NDA resubmission, and preparation for a potential U.S. commercial launch of roluperidone, if approved. Additional news items cover quarterly and annual financial results, changes in research and development and general and administrative expenses, and updates on the company’s cash position.
Governance and leadership developments appear in the news flow as well, including the appointment of new directors with schizophrenia clinical trial experience and a consulting agreement intended to support roluperidone’s late-stage development. For readers interested in CNS drug development, regulatory strategy, and biotech financing structures, the NERV news page provides a centralized view of Minerva’s public communications. Bookmark this page to review new press releases, earnings updates and material 8-K disclosures as they are reported.
Minerva Neurosciences, Inc. (Nasdaq: NERV) reported its first quarter 2022 financial results, highlighting a net loss of $9.8 million, or $0.23 per share, compared to a net loss of $8.8 million, or $0.21 per share for the same period in 2021. R&D expenses rose to $5.0 million due to NDA support activities, while G&A expenses decreased to $3.0 million. The company is preparing to submit a New Drug Application for roluperidone in Q3 2022, following a productive meeting with the FDA. Minerva's cash position stood at $55.0 million as of March 31, 2022.
Minerva Neurosciences (NASDAQ: NERV) announced significant updates regarding the development of roluperidone for treating negative symptoms in schizophrenia. Following a Type C meeting with the FDA on March 2, 2022, the FDA acknowledged the need for effective treatments addressing these symptoms but raised concerns over the applicability of past studies and efficacy data. Despite previous setbacks, Minerva remains committed to submitting a New Drug Application (NDA) for roluperidone this summer, provided additional supportive data can be acquired. The company will discuss further details in a webcast on April 13, 2022.
Minerva Neurosciences (NASDAQ: NERV) reported a net loss of $21.3 million in Q4 2021, a significant increase from a $7.3 million loss in Q4 2020. For the full year, the company incurred a loss of $49.9 million compared to a net income of $1.9 million in 2020. Collaborative revenue dropped to $0 from $41.2 million in the previous year due to a strategic opt-out from a co-development agreement. The company's cash reserves grew to $60.9 million, aided by a $60 million payment from Royalty Pharma. The firm is poised for a potential NDA submission of roluperidone in H1 2022, following a Type C meeting with the FDA.
Minerva Neurosciences announced promising results from its Phase 3 trial of roluperidone for treating negative symptoms in schizophrenia, published in Schizophrenia Bulletin. Involving 513 patients, the study demonstrated that a 64 mg dose significantly improved scores on the Personal and Social Performance scale compared to placebo (p ≤0.021). However, the primary endpoint achieved only nominal significance (p ≤0.044). Despite previous FDA setbacks, the company anticipates submitting a New Drug Application in H1 2022, aiming to fill an unmet need in schizophrenia treatment.
Minerva Neurosciences (NERV) reported third-quarter results, showing a net loss of $9.2 million, or $0.22 per share, compared to a loss of $8.1 million, or $0.19 per share, in Q3 2020. The company plans to request a Type C meeting with the FDA regarding its drug roluperidone, after the FDA denied a pre-NDA meeting request. Cash and equivalents totaled approximately $65.7 million as of September 30, 2021. Key management promotions were also announced, aimed at supporting FDA interactions.
Minerva Neurosciences (Nasdaq: NERV) announced that the FDA denied its request for a pre-NDA meeting for roluperidone and suggested a Type C guidance meeting instead. This meeting will focus on the use of roluperidone as monotherapy for schizophrenia's negative symptoms. Despite this setback, the company maintains its planned NDA submission timeline for the first half of 2022. Currently, no approved treatments exist for the negative symptoms of schizophrenia, highlighting the therapeutic potential of roluperidone.
Minerva Neurosciences (NASDAQ: NERV) will release its Q3 2021 financial results on November 8, 2021. A conference call is scheduled for 8:30 a.m. ET to discuss the results and business updates.
The company, focused on developing therapies for CNS disorders, is currently advancing its pipeline, including roluperidone for schizophrenia and MIN-301 for Parkinson's disease.
Investors can access the live call by dialing (877) 312-5845 (US) or (765) 507-2618 (international).
Minerva Neurosciences has announced leadership changes as part of its strategic plan, promoting Geoff Race to President and Frederick Ahlholm to Chief Financial Officer, effective immediately. These changes come as the company prepares to submit a pre-NDA meeting request to the FDA, aiming for a potential NDA submission in the first half of 2022. Dr. Remy Luthringer expressed confidence in the new leadership to advance the development of roluperidone for treating negative symptoms of schizophrenia. Minerva continues to focus on developing therapies for CNS disorders.
Minerva Neurosciences (Nasdaq: NERV) announced successful results from a pivotal bioequivalence study for roluperidone, aimed at treating negative symptoms of schizophrenia. The study met all key pharmacokinetic objectives, demonstrating bioequivalence between formulations used in late-stage trials and the planned commercial version. This progress is crucial for the upcoming NDA submission to the FDA. The study involved 48 healthy volunteers, confirming that the formulations can be administered with or without food, addressing FDA observations from a prior meeting.
Minerva Neurosciences announced the retirement of Dr. Jay Saoud, Head of Research & Development, who will transition to an advisory role effective September 16, 2021. He will assist with the preparation for a New Drug Application (NDA) for roluperidone. Dr. Ramana Kuchibhatla has been appointed as the new Senior Vice President and Head of Research & Development. Dr. Kuchibhatla brings over 35 years of experience in the life sciences sector, which is expected to support Minerva’s ongoing efforts in developing treatments for CNS disorders.